In an exploratory secondary analysis of the LORELEI trial (329 postmenopausal women, ER+/HER2− early breast cancer), higher BMI was associated with lower response to neoadjuvant letrozole plus placebo (OR 0.90) but not with taselisib plus letrozole (OR 1.03).
Secondary analysisn = 329
Dauccia et al. Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial